盐酸去甲维拉帕米
盐酸去甲维拉帕米 性质
| 熔点 | softens at 50°C, 155-160°C dec. |
|---|---|
| 闪点 | 9℃ |
| 储存条件 | desiccated |
| 溶解度 | H2O: >10 mg/mL |
| 形态 | 固体 |
| 颜色 | 白色 |
| 水溶解性 | H2O: 15mg/mL, clear |
| 稳定性 | 吸湿性 |
| InChI | 1S/C26H36N2O4.ClH/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5;/h8-11,16-17,19,28H,7,12-15H2,1-6H3;1H |
| InChIKey | OEAFTRIDBHSJDC-UHFFFAOYSA-N |
| SMILES | CC(C)C(CCCNCCC1=CC=C(OC)C(OC)=C1)(C#N)C2=CC(OC)=C(OC)C=C2.Cl |
| EPA化学物质信息 | Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, hydrochloride (1:1) (67812-42-4) |
盐酸去甲维拉帕米 用途与合成方法
Calcium channel blocker
P-glycoprotein (P-gp) inhibitor
Norverapamil hydrochloride ((±)-Norverapamil hydrochloride) is similarly effective as verapamil at inhibiting isoniazid and rifampicin tolerance and killing of intracellular M. tuberculosis in the absence of other drugs. norverapamil, also inhibits macrophage-induced tolerance and achieves similar serum levels to verapamil.
Verapamil and its major metabolite norverapamil were identified to be both mechanism-based inhibitors and substrates of CYP3A and reported to have non-linear pharmacokinetics in clinic.
Norverapamil hydrochloride (9 mg/kg; p.o.), a major metabolite of verapamil, has terminal half-life, AUC and Cmax values of 9.4 hours, 260 ng▪h/ml, and 41.6 ng/mL, respectively.
| Animal Model: | Male Sprague-Dawley rats |
| Dosage: | 9 mg/kg (Pharmacokinetic Study) |
| Administration: | Oral administration |
| Result: | t 1/2 =9.4 hours; AUC=260 ng▪h/mL; C max =41.6 ng/mL. |
安全信息
| 危险品运输编号 | UN 2811 6.1/PG 3 |
|---|---|
| WGK Germany | 3 |
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 急性毒性 类别4 经口 眼部刺激 类别2 经皮刺激 类别2 特异性靶器官毒性-一次接触，类别3 |
盐酸去甲维拉帕米 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-100750 | 盐酸去甲维拉帕米 | 67812-42-4 | 1 mg | 400 |
| 2026-09-15 | HY-100750 | 盐酸去甲维拉帕米 | 67812-42-4 | 5mg | 1400 |
